Research Notes

A subscriber to the Site had an interesting find of an article published in the Journal of Surgical Research, describing the placebo controlled clinical study of PAD (Peripheral Arterial Disease) patients with chronic ulcers treated with ADRCs from Celution. By my assessment this study is one of several European Celution device based clinical studies, which culminated in Cytori receiving market authorization (added claim to Celution for intended use of: therapy against chronic wounds- reported August 2012). As described in my other article: Another backdoor Slider,  EU regulations allow the device pathway for same day surgical and AUTOLOGOUS procedures, whereby the extracted cells remain property of the patient and ONLY can be used for this SAME patient as per the "Placed on the Market" principle.  This article is presented in "key elements" style instead of my usual long stories to keep our focus on the facts-

At the closing of the Olympus hardware deal in November 2005, "super-charged" soft tissue transfer wasnt really in the picture of shareholders at all. During the CC of this event the first mention thereof was made as well as the potential of the fistula after Crohn´s and PVD (Peripheral Vascular Disease) applications.

Marc Hedrick mentioned in this conference call- "in addition, plastic and reconstructive surgery and prevascular surgery also represent important digital clinical opportunities that are still in the pre-clinical stage"

Yes-sometime in 2005 (at the time that Olympus was doing its due-diligence) somebody must have gotten the idea, that this type of low hanging fruit was an important part of the technology use and started investigations on graft retention for breast reconstruction after lumpectomy or partial mastectomy. Cytori soon started pre-clinical work on that and in April 2006 Cytori scientist Dr. Min Zhu presented the results of fatgraft retention in rodents at a plastic surgery conference in Miami. The announcement thereof you can read here. LINK HERE

Was an assessment delivered by Lloyd Dean, Chairman of the Cytori Board of Directors concerning the future stockprice of Cytori, during the annual meeting of shareholders in August 2011. Made at a time that most shareholders were moaning about the lack of execution of Cytori management and exactly this guy- certainly not the least influencial- and one of the most  respected CEO´s  in the healthcare space in the US (Catholic Healthcare West- in charge of 12 Billion of Assets and said to have personal "access" to President Obama)- wanted us to believe that Cytori had an excellent management team, for which as of to date- early March 2012 -due to lacking indications (that is relevant news) in respect of accomplishments, no substance to that statement has been provided or can be shown.

This article is 100% hardcore- rather technical, so really for the happy few with ambitions to understand all that jazz. On the other hand, the introduction and its message is provided in the first half, which is really very simple- i.e. fact is, that Cytori management has regarded its shareholders as "dumbo´s" for many years. Has deceived them with "simplicity", keyword- "ischemia or bloodflow", which in itself is totally off-base in respect of the potency of the cell-mix. In the mean time having private investigators unfold and PROVE the gigantic potential of the Gemisch (German: mix), which gemisch can do so much more and really possess a significant ability to regulate the immune system and combat inflammation.. The "solely ischemic" strategy brought the Company on the edge of financial collaps at several occasions in the past, due to concentration of efforts in CHF, which is very expensive per patient and which patients are already severely weakened by toxic conventional medicines, which focus resulted in heavy dilution, since they were "smelling the inflection point", instead of selecting the appropriate disorder fitting to the technology. And I guess everybody understands that.